1802 Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC) by Cortes, J, Crown, J, Awada, A, Schmid, P, Gianni, L, Garcia-Estevez, L, Martinez-Janez, N, Chan, S, Steinberg, J.L, Blaney, M, Tudor, I.C, Uppal, H, Peterson, A, Miller, K, Yardley, D.A, Hudis, C.A, Traina, T.A

Get full text

4MO Homologous recombination (HR) status of platinum-responsive advanced triple-negative breast cancers (aTNBC) treated with olaparib as maintenance therapy by Tan, T.J.Y., Sammons, S., Fink, J.L., Ong, W.S., Jaradi, B., Waring, P., Chan, Y.S.J., Lee, X.P., Lim, B.Y., Brady, J.C., Nixon, A., Traina, T.A., Anders, C., Kim, S-B., Im, Y-H., Dent, R.A.

Get full text

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers by Razavi, Pedram, Chang, Matthew T., Xu, Guotai, Bandlamudi, Chaitanya, Ross, Dara S., Vasan, Neil, Cai, Yanyan, Bielski, Craig M., Donoghue, Mark T.A., Jonsson, Philip, Penson, Alexander, Shen, Ronglai, Pareja, Fresia, Kundra, Ritika, Middha, Sumit, Cheng, Michael L., Zehir, Ahmet, Kandoth, Cyriac, Patel, Ruchi, Huberman, Kety, Smyth, Lillian M., Jhaveri, Komal, Modi, Shanu, Traina, Tiffany A., Dang, Chau, Zhang, Wen, Weigelt, Britta, Li, Bob T., Ladanyi, Marc, Hyman, David M., Schultz, Nikolaus, Robson, Mark E., Hudis, Clifford, Brogi, Edi, Viale, Agnes, Norton, Larry, Dickler, Maura N., Berger, Michael F., Iacobuzio-Donahue, Christine A., Chandarlapaty, Sarat, Scaltriti, Maurizio, Reis-Filho, Jorge S., Solit, David B., Taylor, Barry S., Baselga, José

Get full text